FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027602629> ?p ?o ?g. }

• W2027602629 endingPage "140" @default.
• W2027602629 startingPage "136" @default.
• W2027602629 abstract "Hormone refractory prostate cancer is dominated by osseous metastases leading to bone pain and pathological fractures. We assessed the clinical efficacy of bisphosphonate in the management of symptomatic skeletal metastases due to prostate cancer.A total of 85 patients with painful osseous metastases due to hormone refractory prostate cancer were treated with clodronate in an open prospective nonrandomized clinical study. Clodronate was started as an intravenous phase for 8 days at a dose of 300 mg. daily followed by an oral maintenance phase of 1,600 mg. daily. The primary study end point was decreased pain without an increase in analgesic medication for at least 2 consecutive measurements. Secondary end points were decreased analgesics, an improved Karnofsky index and mobility as well as the duration of bisphosphonate action. Decreased pain was documented by a 10-point visual analog scale and consumption of analgesics was documented in a diary.A palliative response with a significant decrease in mean pain score from 7.9 (range 6 to 10) to 2.5 (range 0 to 4) (p <0.001) was achieved in 64 of the 85 patients (75%), 19 (22%) were completely pain-free without further need of analgesics and 45 significantly decreased the daily consumption of analgesics. The mean duration of bisphosphonate action was 9 weeks (range 4 to 22) and mean survival was 12 weeks (range 6 to 22). Improvement in bone pain was paralleled by an improvement in the mean Karnofsky index of 45% (range 30% to 60%) to 70% (range 50% to 80%) at the end of the treatment period.Bisphosphonate treatment of painful osseous metastases due to hormone refractory prostate cancer results in a significant pain decrease and a significant decrease in the daily consumption of analgesics in 75% of patients. Each characteristic is paralleled by an increase in the Karnofsky index, mainly due to better mobility. Bisphosphonate should have a definite role in the palliative management of symptomatic hormone refractory prostate cancer." @default.
• W2027602629 created "2016-06-24" @default.
• W2027602629 creator A5043779249 @default.
• W2027602629 creator A5048118430 @default.
• W2027602629 creator A5073359794 @default.
• W2027602629 date "2001-01-01" @default.
• W2027602629 modified "2023-10-10" @default.
• W2027602629 title "THE USE OF BISPHOSPHONATE FOR THE PALLIATIVE TREATMENT OF PAINFUL BONE METASTASIS DUE TO HORMONE REFRACTORY PROSTATE CANCER" @default.
• W2027602629 cites W145854241 @default.
• W2027602629 cites W1854708637 @default.
• W2027602629 cites W1893347245 @default.
• W2027602629 cites W1937662086 @default.
• W2027602629 cites W1967168865 @default.
• W2027602629 cites W1972448628 @default.
• W2027602629 cites W1976128207 @default.
• W2027602629 cites W1978960998 @default.
• W2027602629 cites W2003949207 @default.
• W2027602629 cites W2005885733 @default.
• W2027602629 cites W2026888556 @default.
• W2027602629 cites W2066014756 @default.
• W2027602629 cites W2083148552 @default.
• W2027602629 cites W2088392474 @default.
• W2027602629 cites W2093871127 @default.
• W2027602629 cites W2099008973 @default.
• W2027602629 cites W2103009146 @default.
• W2027602629 cites W2134661141 @default.
• W2027602629 cites W2314428698 @default.
• W2027602629 cites W2403355975 @default.
• W2027602629 cites W2415481317 @default.
• W2027602629 cites W2498788895 @default.
• W2027602629 cites W1972975245 @default.
• W2027602629 doi "https://doi.org/10.1097/00005392-200101000-00033" @default.
• W2027602629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11125382" @default.
• W2027602629 hasPublicationYear "2001" @default.
• W2027602629 type Work @default.
• W2027602629 sameAs 2027602629 @default.
• W2027602629 citedByCount "113" @default.
• W2027602629 countsByYear W20276026292012 @default.
• W2027602629 countsByYear W20276026292013 @default.
• W2027602629 countsByYear W20276026292014 @default.
• W2027602629 countsByYear W20276026292016 @default.
• W2027602629 countsByYear W20276026292017 @default.
• W2027602629 countsByYear W20276026292019 @default.
• W2027602629 countsByYear W20276026292020 @default.
• W2027602629 countsByYear W20276026292022 @default.
• W2027602629 crossrefType "journal-article" @default.
• W2027602629 hasAuthorship W2027602629A5043779249 @default.
• W2027602629 hasAuthorship W2027602629A5048118430 @default.
• W2027602629 hasAuthorship W2027602629A5073359794 @default.
• W2027602629 hasConcept C121332964 @default.
• W2027602629 hasConcept C121608353 @default.
• W2027602629 hasConcept C126322002 @default.
• W2027602629 hasConcept C126894567 @default.
• W2027602629 hasConcept C141071460 @default.
• W2027602629 hasConcept C14184104 @default.
• W2027602629 hasConcept C142424586 @default.
• W2027602629 hasConcept C159110408 @default.
• W2027602629 hasConcept C188816634 @default.
• W2027602629 hasConcept C2776139714 @default.
• W2027602629 hasConcept C2776235491 @default.
• W2027602629 hasConcept C2776541429 @default.
• W2027602629 hasConcept C2777251235 @default.
• W2027602629 hasConcept C2777783956 @default.
• W2027602629 hasConcept C2779013556 @default.
• W2027602629 hasConcept C2780192828 @default.
• W2027602629 hasConcept C2780820201 @default.
• W2027602629 hasConcept C2994186709 @default.
• W2027602629 hasConcept C42219234 @default.
• W2027602629 hasConcept C71924100 @default.
• W2027602629 hasConcept C87355193 @default.
• W2027602629 hasConceptScore W2027602629C121332964 @default.
• W2027602629 hasConceptScore W2027602629C121608353 @default.
• W2027602629 hasConceptScore W2027602629C126322002 @default.
• W2027602629 hasConceptScore W2027602629C126894567 @default.
• W2027602629 hasConceptScore W2027602629C141071460 @default.
• W2027602629 hasConceptScore W2027602629C14184104 @default.
• W2027602629 hasConceptScore W2027602629C142424586 @default.
• W2027602629 hasConceptScore W2027602629C159110408 @default.
• W2027602629 hasConceptScore W2027602629C188816634 @default.
• W2027602629 hasConceptScore W2027602629C2776139714 @default.
• W2027602629 hasConceptScore W2027602629C2776235491 @default.
• W2027602629 hasConceptScore W2027602629C2776541429 @default.
• W2027602629 hasConceptScore W2027602629C2777251235 @default.
• W2027602629 hasConceptScore W2027602629C2777783956 @default.
• W2027602629 hasConceptScore W2027602629C2779013556 @default.
• W2027602629 hasConceptScore W2027602629C2780192828 @default.
• W2027602629 hasConceptScore W2027602629C2780820201 @default.
• W2027602629 hasConceptScore W2027602629C2994186709 @default.
• W2027602629 hasConceptScore W2027602629C42219234 @default.
• W2027602629 hasConceptScore W2027602629C71924100 @default.
• W2027602629 hasConceptScore W2027602629C87355193 @default.
• W2027602629 hasIssue "1" @default.
• W2027602629 hasLocation W20276026291 @default.
• W2027602629 hasLocation W20276026292 @default.
• W2027602629 hasOpenAccess W2027602629 @default.
• W2027602629 hasPrimaryLocation W20276026291 @default.
• W2027602629 hasRelatedWork W1975355570 @default.
• W2027602629 hasRelatedWork W1975881851 @default.

• next